Does Ozempic cause skin cancer? What the latest data shows

The short answer

No. The largest analysis to date found that starting a GLP-1 receptor agonist like Ozempic, Wegovy or Mounjaro did not raise the risk of melanoma, the most serious skin cancer. Researchers matched hundreds of thousands of adults with type 2 diabetes and followed them for up to three years. A faint signal for non-melanoma skin cancer turned up in one comparison, but it was small, did not hold across groups, and disappeared once the researchers corrected for how closely GLP-1 users tend to get watched by their doctors. If a social-media post has scared you into thinking Ozempic causes skin cancer, the current data should settle most of that worry. There are a few honest caveats, and they are below.

Does Ozempic cause skin cancer? Why the question came up

The concern is not completely out of nowhere. GLP-1 receptors show up in skin tissue, and any drug taken by tens of millions of people gets scrutinised for cancer signals. Earlier, smaller reports hinted in different directions, and the rapid growth of these medications left a gap between how many people use them and how much long-term safety data exists. That gap is exactly where fear and headlines breed.

A study published in Diabetes, Obesity and Metabolism in 2026 set out to close part of that gap for skin cancer specifically. The researchers used a method called target trial emulation, which tries to mimic the design of a randomised trial using real-world records. They drew on the TriNetX network of United States electronic health records from 2014 to 2025, focusing only on adults with type 2 diabetes who were newly starting a medication.

The clever part is the comparison. Instead of measuring GLP-1 users against the general population, which would be an unfair match, they compared people who started a GLP-1 drug against people who started one of two other diabetes drugs: an SGLT2 inhibitor or a DPP-4 inhibitor. Those comparison patients are similar in age, diabetes severity and health-seeking behaviour, so the comparison isolates the drug rather than the kind of person who takes it.

What the study found on melanoma and non-melanoma skin cancer

The headline result is reassuring. Across both comparisons, GLP-1 medications were not linked to a higher risk of melanoma. The study tracked two skin cancer outcomes over three years: melanoma, the serious kind that can spread, and non-melanoma skin cancer (NMSC), the far more common basal cell and squamous cell cancers that are usually local and treatable.

• Melanoma versus SGLT2 inhibitors. Among 235,797 matched pairs, there were 583 melanoma cases in GLP-1 users versus 557 in the comparison group. The hazard ratio was 1.04 (95% confidence interval 0.93 to 1.17), which is statistically no different from no effect.
• Melanoma versus DPP-4 inhibitors. Among 153,873 matched pairs, 431 melanoma cases versus 389. The hazard ratio was 1.09 (0.95 to 1.25), again crossing 1.0 and so not significant.
• Non-melanoma skin cancer. Here one comparison showed a borderline bump: a hazard ratio of 1.06 (1.00 to 1.11) versus SGLT2 inhibitors. Against DPP-4 inhibitors there was no significant difference (1.03, 0.97 to 1.09).

To put the melanoma numbers in human terms, the incidence worked out to roughly 1.3 cases per 1,000 person-years in both groups. That is a small background rate, and the GLP-1 and comparison arms sat right on top of each other. The authors stated it plainly: GLP-1 receptor agonist use was not associated with an increased risk of melanoma compared with either comparison drug.

Why the non-melanoma blip is probably not a real effect

That single borderline NMSC result is where an honest article earns its keep. A hazard ratio of 1.06 with a confidence interval that just touches 1.00 is the statistical equivalent of a whisper. More importantly, it did not behave like a true drug effect. It appeared against one comparison drug but not the other, and real biological effects usually show up consistently.

The researchers then ran a technique called negative control outcome calibration. The idea is simple: they checked outcomes that the drug could not plausibly cause, saw how much false signal the data produced on its own, and adjusted for it. After that correction, the NMSC signal fell to a hazard ratio of 0.98 versus SGLT2 inhibitors and 1.00 versus DPP-4 inhibitors. In plain language, it vanished.

There is also a human-behaviour explanation. People who start a GLP-1 drug see their doctors more often and may get looked at more closely, so small, slow-growing skin cancers are simply more likely to be spotted and recorded. That is detection, not causation. When a tiny signal only appears in one comparison and evaporates after calibration, the most likely story is leftover bias rather than the drug. This is the same discipline we apply whenever a GLP-1 side effect first surfaces as a statistical flag: a signal is a reason to look closer, not a verdict.

What this study cannot tell you

Reassuring is not the same as settled, and the authors were upfront about the limits. The biggest one is time. Average follow-up was only about 1.8 to 2.2 years, with a maximum of three. Melanoma can take many years to develop, so a two-year window may be too short to catch a slow-emerging risk, especially for long-acting drugs like semaglutide (the molecule in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound). The study answers "is there an early signal," not "is it safe forever."

Two other caveats matter. First, skin cancers were identified from diagnosis codes, and the accuracy of those codes was only about 58% for melanoma, meaning some recorded cases were not true melanomas. Second, the records had no information on the things that actually drive skin cancer the most: ultraviolet exposure, skin type, sunburn history, occupation and family history. The matching cannot balance what it cannot see. So the fair summary is this: over roughly two years, there was no melanoma signal and no convincing non-melanoma signal, which is genuinely good news, but longer studies are still needed.

How to protect your skin on a GLP-1 drug

A GLP-1 drug does not appear to raise your skin cancer risk, but it also does nothing to lower the risk you already carry from the sun and your genes. So the sensible move is to keep doing the ordinary things that protect everyone, and to add a couple that matter more during fast weight loss.

• Keep up skin checks. Do a monthly self-exam and keep any routine dermatology screening your doctor already recommends. Weight-loss medication does not change that schedule.
• Learn the ABCDE warning signs of melanoma. Asymmetry, an irregular Border, more than one Colour, a Diameter larger than a pencil eraser, and any mole that is Evolving in size, shape or colour. A new or changing spot deserves a professional look.
• Use everyday sun protection. Broad-spectrum sunscreen, shade in peak hours and covering up remain the only proven ways to lower skin cancer risk. No pill and no supplement does this job.
• Feed your skin during rapid weight loss. Eating far less can short your skin of the building blocks it uses to repair itself, including protein, vitamin A, vitamin C, zinc and omega-3 fats. Prioritising protein and colourful produce supports skin quality while you lose weight.
• Test, do not guess, if symptoms appear. Slow wound healing, very dry skin or brittle nails can point to a nutrient gap rather than anything sinister. A blood panel is the way to find out.

It helps to separate two different skin conversations. This article is about cancer risk, and the news there is good. A separate issue is skin quality: the sagging and thinning some people call "Ozempic face," which comes from losing fat and, in part, from running low on skin-supporting nutrients. We cover that in detail in what GLP-1 medications do to your skin and what helps. The nutrient angle is where a measured, repletion-first approach fits, and it is exactly what GLP-1 Shield is built around. Supplements do not treat or prevent skin cancer, and they are no substitute for sunscreen or a dermatologist, but closing a genuine deficiency helps your skin do its everyday repair work. If you want to know which nutrients tend to slip and how to track them, our monitoring guide for vitamins on GLP-1 lays out the panel to ask for.

One last piece of context. GLP-1 medications are increasingly linked to lower rates of several cancers in large datasets, which is the opposite of the fear that drove this question. For the wider picture, see what the evidence shows on GLP-1 drugs and overall cancer risk.

Key takeaways

• A 2026 target trial emulation of adults with type 2 diabetes found GLP-1 medications were not linked to higher melanoma risk (hazard ratios 1.04 and 1.09, both non-significant).
• A borderline non-melanoma skin cancer signal appeared in one comparison but disappeared after statistical calibration, pointing to bias rather than a real effect.
• Melanoma occurred at about 1.3 cases per 1,000 person-years in both GLP-1 users and the comparison groups.
• The main limit is time: average follow-up was roughly two years, which may be too short to rule out a slow-growing risk, so longer studies are still needed.
• Keep up sun protection and skin checks, learn the ABCDE melanoma signs, and feed your skin enough protein and nutrients during rapid weight loss. No supplement prevents skin cancer.

Frequently asked questions

Does Ozempic cause skin cancer?

Current evidence does not show that Ozempic causes skin cancer. In a 2026 target trial emulation of adults with type 2 diabetes, starting a GLP-1 drug was not linked to a higher risk of melanoma compared with two other diabetes medications (hazard ratios 1.04 and 1.09, both non-significant). A faint signal for non-melanoma skin cancer appeared in one comparison but vanished after statistical calibration, so it likely reflects bias rather than a real effect.

Can GLP-1 drugs like Wegovy or Mounjaro cause melanoma?

The data so far says no. The 2026 study compared 235,797 GLP-1 users against a matched group and found 583 melanoma cases versus 557, a difference that was not statistically significant. The result held across both comparison drugs. The main caveat is time: average follow-up was about two years, which may be too short to rule out a slow-growing risk, so this is reassuring rather than final.

Should I still get skin checks while on Ozempic or Wegovy?

Yes. A GLP-1 drug does not remove your baseline skin cancer risk, which is driven mostly by sun exposure, skin type and family history. Keep up routine skin self-exams, watch any mole that changes in size, shape or colour, and see a dermatologist for anything new or growing. People with a personal or family history of skin cancer should follow their usual screening schedule regardless of which weight-loss medication they take.

Does rapid weight loss on a GLP-1 affect your skin?

Rapid weight loss and reduced eating can leave your skin short of the nutrients it uses to repair itself, such as vitamin A, vitamin C, zinc and protein, and can contribute to the sagging known as Ozempic face. This is a skin-quality issue, not a cancer risk. Eating enough protein and colourful produce, and testing for deficiencies if symptoms appear, supports skin health during fast weight loss.